Genprex, Inc. Q2 2024 10-Q Filing
Ticker: GNPX · Form: 10-Q · Filed: Aug 9, 2024 · CIK: 1595248
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Genprex Q2 10-Q: $179.5K assets, focus on pharma prep. **Check financials.**
AI Summary
Genprex, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $179,550 as of June 30, 2024. The filing details financial performance and operational updates for the second quarter of 2024.
Why It Matters
This filing provides investors with a quarterly update on Genprex's financial health and operational progress, crucial for understanding the company's trajectory in the pharmaceutical preparations sector.
Risk Assessment
Risk Level: medium — As a company in the pharmaceutical preparations sector, Genprex faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- $179.5K — Total Assets (As of June 30, 2024)
Key Players & Entities
- Genprex, Inc. (company) — Filer of the 10-Q
- 20240630 (date) — End of reporting period
- $179,550 (dollar_amount) — Total assets as of June 30, 2024
FAQ
What were Genprex, Inc.'s total assets as of June 30, 2024?
Genprex, Inc.'s total assets were $179,550 as of June 30, 2024.
What is the fiscal year end for Genprex, Inc.?
Genprex, Inc.'s fiscal year ends on December 31.
What is the Standard Industrial Classification code for Genprex, Inc.?
The SIC code for Genprex, Inc. is 2834, Pharmaceutical Preparations.
What is the SEC file number for Genprex, Inc.?
The SEC file number for Genprex, Inc. is 001-38244.
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending June 30, 2024.
Filing Stats: 4,512 words · 18 min read · ~15 pages · Grade level 16.7 · Accepted 2024-08-09 16:31:26
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share GNPX The Nasdaq Capital M
Filing Documents
- gnpx20240630_10q.htm (10-Q) — 904KB
- ex_677330.htm (EX-31.1) — 16KB
- ex_677331.htm (EX-31.2) — 14KB
- ex_677332.htm (EX-32.1) — 8KB
- 0001437749-24-025893.txt ( ) — 4564KB
- gnpx-20240630.xsd (EX-101.SCH) — 39KB
- gnpx-20240630_cal.xml (EX-101.CAL) — 19KB
- gnpx-20240630_def.xml (EX-101.DEF) — 277KB
- gnpx-20240630_lab.xml (EX-101.LAB) — 263KB
- gnpx-20240630_pre.xml (EX-101.PRE) — 296KB
- gnpx20240630_10q_htm.xml (XML) — 691KB
FINANCIAL STATEMENTS
FINANCIAL STATEMENTS 3 Condensed Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023 3 Condensed Statements of Operations for the Three and Six Months Ended June 30, 2024, and 2023 (unaudited) 4 Condensed Statements of Changes in Stockholders' Equity for the Three and Six Months Ended June 30, 2024, and 2023 (unaudited) 5 Condensed Statements of Cash Flows for the Six Months Ended June 30, 2024, and 2023 (unaudited) 6 Notes to Unaudited Condensed Financial Statements 7 ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 21 ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 28 ITEM 4.
CONTROLS AND PROCEDURES
CONTROLS AND PROCEDURES 28 PART II OTHER INFORMATION 29 ITEM 1.
LEGAL PROCEEDINGS
LEGAL PROCEEDINGS 29 ITEM 1A.
RISK FACTORS
RISK FACTORS 29 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 29 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 29 ITEM 4. MINE SAFETY DISCLOSURES 29 ITEM 5. OTHER INFORMATION 29 ITEM 6. EXHIBITS 29
SIGNATURES
SIGNATURES 31 2 Table of Contents
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements Genprex, Inc. Condensed Balance Sheets June 30, December 31, 2024 2023 Assets (unaudited) (see Note 2) Current assets: Cash and cash equivalents $ 2,459,024 $ 6,737,629 Prepaid expenses and other 1,935,787 794,138 Total current assets 4,394,811 7,531,767 Property and equipment, net 1,735 7,859 Other non-current assets: Security deposits 10,000 10,000 Research and development supplies 2,198,264 2,347,488 Intellectual property, net — 773,478 Total other assets 2,208,264 3,130,966 Total assets $ 6,604,810 $ 10,670,592 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,174,800 $ 1,397,610 Other current liabilities 1,084,460 1,856,598 Total current liabilities 2,259,260 3,254,208 Commitments and contingencies (Note 7) Stockholders' equity: Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2024, and December 31, 2023, respectively — — Common stock $0.001 par value: 200,000,000 shares authorized; 2,555,735 and 1,485,902 shares issued and outstanding at June 30, 2024, and December 31, 2023, respectively 2,556 1,486 Additional paid-in capital 150,495,988 141,103,178 Accumulated deficit ( 146,152,994 ) ( 133,688,280 ) Total stockholders' equity 4,345,550 7,416,384 Total liabilities and stockholders' equity $ 6,604,810 $ 10,670,592 See accompanying notes to the unaudited condensed financial statements. 3 Table of Contents Genprex, Inc. Condensed Statements of Operations (unaudited) Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Operating expenses: Depreciation $ 2,288 $ 3,837 $ 4,958 $ 7,853 Research and development 1,666,522 3,976,917 4,940,902 9,287,065 General and administrative 4,849,472 4,057,197 7,569,140 8,007,587 Total operating expenses 6,